Core Viewpoint - ADIA Nutrition Inc. is hosting a webinar on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis (MS) and other autoimmune conditions, aiming to educate shareholders, supporters, and potential investors about the therapy and its benefits [1][3]. Company Overview - ADIA Nutrition Inc. is based in Winter Park, Florida, and is publicly traded on OTCQB under the ticker ADIA. The company focuses on advancing healthcare through innovation, particularly in stem cell and regenerative products [6]. - The company operates through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products, and is growing its network of Adia Med clinics that specialize in various regenerative treatments [6][7]. Webinar Details - The webinar is scheduled for November 20, 2025, at 6:30 PM EST, featuring Dr. Evan Thomas, the Medical Director of Adia Med, who will discuss the science and patient outcomes related to HSCT [4][5]. - The event aims to provide insights into the compliant approach of Adia Med in delivering HSCT therapy to U.S. patients [4]. Treatment Focus - The webinar will specifically address HSCT as a treatment option for MS and other autoimmune conditions, highlighting its potential to improve patient outcomes [3][4]. - A testimonial from Larry Powalisz, CEO of ADIA Nutrition, emphasizes the life-changing impact of HSCT, showcasing its effectiveness in treating MS [4]. Business Model - ADIA Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [7]. - The company is also involved in strategic partnerships with aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [7].